<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82141">
  <stage>Registered</stage>
  <submitdate>6/07/2007</submitdate>
  <approvaldate>13/07/2007</approvaldate>
  <actrnumber>ACTRN12607000368437</actrnumber>
  <trial_identification>
    <studytitle>Safety and Immunogenecity Study of an E.Coli Expressed Particulate Recombinant Hepatitis E Vaccine</studytitle>
    <scientifictitle>Safety and Immunogenecity Study of an E.Coli Expressed Particulate Recombinant Hepatitis E Vaccine</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis E</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Liver</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intervention: hepatitis E (HE) vaccine
The subjects were randomized and assigned to groups to administrate intramuscular injection either two 20µg HE vaccine doses (0 month, 6th month), three 10µg, 20µg, 30µg or 40 µg of HE vaccine 20 µg dose (0 month, 1st month, 6th month) respectively. 

Participants received intervention treatment or control treatment will be followed-up for 1 month after the last vaccination.</interventions>
    <comparator>Control treatment: commercial hepatitis B vaccine
The subjects were randomly assigned to group to administrate intramuscular injection three 5µg commercial hepatitis B vaccine doses (0 month, 1st month, 6th month). </comparator>
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Seroconversion rate of immunoglobulin gamman (IgG) antibody against hepatitis E virus (HEV).</outcome>
      <timepoint>At one month after the last intervention</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Level of IgG antibody against hepatitis E virus</outcome>
      <timepoint>At baseline and at 0, 1 and 7 months after the last intervention</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Novel infection rate of hepatitis E virus</outcome>
      <timepoint>At 0, 1, and 7 months after the last intervention</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy; willing to comply the protocol; have not been adminastrated with any other preventive products such as vaccine or immunoglobulin.</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Any anaphylaxis history to vaccination or medicine; any neurotic or mental disease history or family history; impediment of cruor; any confirmed or possible immuno-deficiency; any active infection; serious liver,  kidney, or cardio-vascular diseases; malignant tumor, serious asthma; spleen removal; hypertension; pregnant or lactatation period woman; fever; antibody against hepatitis E virus (anti-HEV) positive; alanine transaminase abnormal; blood urea nitrogen abnormal; glucose abnormal; Hepatitis B virus surface antigen (HBsAg) positive.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation is not concealed</concealment>
    <sequence>Simple randomisation by using a randomization table created by computer software</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>The people receiving the vaccines, the people administering the vaccination and the people assessing the outcomes were blinded.</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>7/01/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>600</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Xiamen YangShengTang Biotechnic Ltd.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>China</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Ministry of Science and Technology of China</fundingname>
      <fundingaddress />
      <fundingcountry>China</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Xiamen YangShengTang Biotechnic Ltd</fundingname>
      <fundingaddress />
      <fundingcountry>China</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>National Institute of Diagnostics and Vaccine Development in infectious disease, Xiamen University</sponsorname>
      <sponsoraddress />
      <sponsorcountry>China</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of the protocol is to evaluate the safety and immunogenicity of an E.coli expressed particulate recombinant hepatitis E vaccine. The study hypothesis is that the vaccine induce significant seroconversion of IgG anti-HEV in healthy subjects, and the vaccine is tolerable for healthy adults.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The institutional review boards of Guangxi Province-Liucheng county</ethicname>
      <ethicaddress />
      <ethicapprovaldate>29/12/2004</ethicapprovaldate>
      <hrec>IRB00001594</hrec>
      <ethicsubmitdate />
      <ethiccountry>China</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The institutional review boards of Guangxi Province-Mengshan county</ethicname>
      <ethicaddress />
      <ethicapprovaldate>29/03/2005</ethicapprovaldate>
      <hrec>IRB00001594</hrec>
      <ethicsubmitdate />
      <ethiccountry>China</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jun Zhang</name>
      <address>National Institute of Diagnostics and Vaccine Development in Infectious Disease (NIDVD)
Xiamen University
Xiamen Fujian 361005</address>
      <phone>0086 592 2183111</phone>
      <fax>0086 592 2181258</fax>
      <email>zhangj@xmu.edu.cn</email>
      <country>China</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jun Zhang</name>
      <address>National Institute of Diagnostics and Vaccine Development in Infectious Disease (NIDVD)
Xiamen University
Xiamen Fujian 361005</address>
      <phone>0086 592 2183111</phone>
      <fax>0086 592 2181258</fax>
      <email>zhangj@xmu.edu.cn</email>
      <country>China</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>